Boehringer Ingelheim’s volasertib showed in a Phase II study an improvement in overall survival in older AML patients
9 July 2014 | By Boehringer Ingelheim
Results from a Phase II study, published in the American Society of Hematology journal Blood, showed patients with previously untreated acute myeloid leukemia aged 65 or older and ineligible for intensive remission induction therapy, lived longer...